Switch theme
Sign up to access all valuation multiples
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
1956
125K+
LTM Revenue $43.2B
LTM EBITDA $10.8B
$180B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Thermo Fisher Scientific has a last 12-month revenue (LTM) of $43.2B and a last 12-month EBITDA of $10.8B.
In the most recent fiscal year, Thermo Fisher Scientific achieved revenue of $42.9B and an EBITDA of $11.5B.
Thermo Fisher Scientific expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Thermo Fisher Scientific valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $43.2B | XXX | $42.9B | XXX | XXX | XXX |
| Gross Profit | $18.1B | XXX | $17.7B | XXX | XXX | XXX |
| Gross Margin | 42% | XXX | 41% | XXX | XXX | XXX |
| EBITDA | $10.8B | XXX | $11.5B | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $9.7B | XXX | $7.7B | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $8.4B | XXX | $6.3B | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $27.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Thermo Fisher Scientific's stock price is $403.
Thermo Fisher Scientific has current market cap of $152B, and EV of $180B.
See Thermo Fisher Scientific trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $180B | $152B | XXX | XXX | XXX | XXX | $22.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Thermo Fisher Scientific has market cap of $152B and EV of $180B.
Thermo Fisher Scientific's trades at 4.2x EV/Revenue multiple, and 15.6x EV/EBITDA.
Equity research analysts estimate Thermo Fisher Scientific's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Thermo Fisher Scientific has a P/E ratio of 18.1x.
See valuation multiples for Thermo Fisher Scientific and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $152B | XXX | $152B | XXX | XXX | XXX |
| EV (current) | $180B | XXX | $180B | XXX | XXX | XXX |
| EV/Revenue | 4.2x | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | 16.6x | XXX | 15.6x | XXX | XXX | XXX |
| EV/EBIT | 18.5x | XXX | 23.4x | XXX | XXX | XXX |
| EV/Gross Profit | 9.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.1x | XXX | 24.0x | XXX | XXX | XXX |
| EV/FCF | 24.7x | XXX | 24.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialThermo Fisher Scientific's last 12 month revenue growth is 4%
Thermo Fisher Scientific's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Thermo Fisher Scientific's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Thermo Fisher Scientific's rule of X is 34% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Thermo Fisher Scientific and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | -1% | XXX | XXX | XXX |
| Rule of 40 | 29% | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Thermo Fisher Scientific acquired XXX companies to date.
Last acquisition by Thermo Fisher Scientific was XXXXXXXX, XXXXX XXXXX XXXXXX . Thermo Fisher Scientific acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Thermo Fisher Scientific founded? | Thermo Fisher Scientific was founded in 1956. |
| Where is Thermo Fisher Scientific headquartered? | Thermo Fisher Scientific is headquartered in United States of America. |
| How many employees does Thermo Fisher Scientific have? | As of today, Thermo Fisher Scientific has 125K+ employees. |
| Who is the CEO of Thermo Fisher Scientific? | Thermo Fisher Scientific's CEO is Mr. Marc N. Casper. |
| Is Thermo Fisher Scientific publicy listed? | Yes, Thermo Fisher Scientific is a public company listed on NYS. |
| What is the stock symbol of Thermo Fisher Scientific? | Thermo Fisher Scientific trades under TMO ticker. |
| When did Thermo Fisher Scientific go public? | Thermo Fisher Scientific went public in 1980. |
| Who are competitors of Thermo Fisher Scientific? | Similar companies to Thermo Fisher Scientific include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of Thermo Fisher Scientific? | Thermo Fisher Scientific's current market cap is $152B |
| What is the current revenue of Thermo Fisher Scientific? | Thermo Fisher Scientific's last 12 months revenue is $43.2B. |
| What is the current revenue growth of Thermo Fisher Scientific? | Thermo Fisher Scientific revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Thermo Fisher Scientific? | Current revenue multiple of Thermo Fisher Scientific is 4.2x. |
| Is Thermo Fisher Scientific profitable? | Yes, Thermo Fisher Scientific is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Thermo Fisher Scientific? | Thermo Fisher Scientific's last 12 months EBITDA is $10.8B. |
| What is Thermo Fisher Scientific's EBITDA margin? | Thermo Fisher Scientific's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Thermo Fisher Scientific? | Current EBITDA multiple of Thermo Fisher Scientific is 16.6x. |
| What is the current FCF of Thermo Fisher Scientific? | Thermo Fisher Scientific's last 12 months FCF is $7.3B. |
| What is Thermo Fisher Scientific's FCF margin? | Thermo Fisher Scientific's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Thermo Fisher Scientific? | Current FCF multiple of Thermo Fisher Scientific is 24.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
